ClinicalTrialsFinder
RecruitingPhase 1NCT07108114

SLV-324 Treatment of Metastatic Solid Tumors

A Phase 1 Dose-Escalation Study of SLV-324 in Subjects With Metastatic Solid Tumors

Sponsor

Solve Therapeutics

Enrollment

70 participants

Start Date

Aug 25, 2025

Study Type

INTERVENTIONAL

Conditions

Metastatic Solid Tumors

Summary

This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-324 across a range of dose levels when administered to subjects with metastatic solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SLV-324 intravenous (IV infusion) for people with metastatic solid tumors. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSLV-324 intravenous (IV infusion)

SLV-324 will be administered as an IV infusion

Locations(7)

Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States

Washington University

St Louis, Missouri, United States

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

MD Anderson Cancer Center

Houston, Texas, United States

Mays Cancer Center; University of Texas Health San Antonio

Houston, Texas, United States

University of Washington / Fred Hutchinson Cancer Center

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07108114

Related Trials

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

NCT0585336725 locations

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

NCT069837435 locations

ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers

NCT072380759 locations

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT0603144118 locations

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

NCT03093116165 locations